Over the last half-decade, we have witnessed game-changing developments within the cannabinoid field, driving it into a new era of rigorous research, promising clinical trials and multimillion-doll
An investigator-led trial of Jazz Pharma's cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain cancer - will get underway in the UK next year.
The use of medical cannabis in the UK has moved a step closer, after the home secretary asked for advice following a review that concluded that there is evidence of therapeutic benefit.
It’s been a week notable for developments in neurology medicine, with Celgene exercising an option to buy a potential multiple sclerosis drug, as GW Pharma prepares a filing for a phase 3 e
Biogen has scaled back its ambitions for Denali-partnered Parkinson’s disease candidate BIIB122, abandoning a complex and likely costly phase 3 trial that isn’t due to com
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas